Dataset Information

Normobaric oxygen: a novel approach for treating chronic cerebral circulation insufficiency.

ABSTRACT: Chronic cerebral circulation insufficiency (CCCI) is viewed as an alarming state induced by long-term reduction in cerebral perfusion, which is associated with neurological deficits and high risk of stroke occurrence or recurrence. CCCI accounts for a large proportion of both outpatients and inpatients with cerebrovascular diseases, while management of CCCI remains a formidable challenge to clinicians. Normobaric oxygen (NBO) is an adjuvant hyperoxygenation intervention supplied with one atmosphere pressure (1 ATA =101.325 kPa). A plethora of studies have demonstrated the efficacy of NBO on the penumbra in acute stroke. NBO has been shown to increase the oxygen pressure, raise the intracranial blood flow, protect blood-brain barrier and enhance neuroprotective effects. As similar underlying mechanisms are shared by the penumbra in stroke and the ischemic-hypoxic brain tissues in CCCI, we speculate that NBO may serve as a promising therapeutic strategy for attenuating short-term symptoms or improving long-term clinical outcomes among patients with CCCI. Due to the scant research exploring the efficacy and safety of NBO for treating CCCI so far, both experimental and clinical studies are warranted to verify our hypothesis in the future.

SUBMITTER: Ding J

PROVIDER: S-EPMC6421875 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Normobaric oxygen: a novel approach for treating chronic cerebral circulation insufficiency.

Ding Jiayue J Zhou Da D Liu Cheng C Pan Liqun L Ya Jingyuan J Ding Yuchuan Y Ji Xunming X Meng Ran R

Clinical interventions in aging 20190314

Chronic cerebral circulation insufficiency (CCCI) is viewed as an alarming state induced by long-term reduction in cerebral perfusion, which is associated with neurological deficits and high risk of stroke occurrence or recurrence. CCCI accounts for a large proportion of both outpatients and inpatients with cerebrovascular diseases, while management of CCCI remains a formidable challenge to clinicians. Normobaric oxygen (NBO) is an adjuvant hyperoxygenation intervention supplied with one atmosph ...[more]

PMID: 30936686

Similar Datasets

Project description:To evaluate the safety and clinical efficacy of Yangxue Qingnao (YXQN) granules in the treatment of chronic cerebral circulation insufficiency (CCCI), electronic databases-PubMed, Embase, CNKI, VIP, and Wangfang-were searched for randomized controlled trials (RCTs) published up to January 2019. GRADE and RevMan 5.3.0 were used for grading and analysis, respectively. Fifteen trials involving 1211 CCCI patients were included. Subgroup analysis was performed owing to study heterogeneity. Compared to nimodipine plus routine treatment, YXQN granules plus routine treatment were more effective in increasing basilar artery (BA) blood flow velocity (mean difference (MD)?=?3.34, 95% confidence interval (CI)?=?[2.31, 4.37], P < 0.00001), vertebral artery (VA) blood flow velocity (MD?=?0.52, 95% CI?=?[0.27, 0.76], P < 0.0001), and internal carotid artery (ICA) blood flow velocity (MD?=?7.46, 95% CI?=?[2.01, 12.90], P=0.007). In improving the clinical efficacy of traditional Chinese medicine (TCM) for symptoms such as headache, dizziness, and insomnia, YXQN granules plus routine treatment were shown to be superior to the following control treatments: nimodipine plus routine treatment (mean difference (M-H)?=?4.21, 95% CI?=?[2.49, 7.12], P < 0.00001), flunarizine plus routine treatment (mean difference (M-H)?=?3.92, 95% CI?=?[1.36, 11.29], P=0.01), troxerutin plus routine treatment (mean difference (M-H)?=?4.79, 95% CI?=?[2.20, 10.42], P < 0.00001), and routine treatment (mean difference (M-H)?=?6.13, 95% CI?=?[1.48, 25.34], P=0.01). Risk of bias was assessed in 15 trials. One analysis was graded using GRADE and showed poor results. Adverse events were not reported explicitly in all but one trial. Thus, this meta-analysis suggests that YXQN granules may be beneficial for patients with CCCI. However, owing to the poor quality of the clinical trials and small sample sizes, a definite conclusion on the efficacy and safety of YXQN granules cannot be drawn from existing information.

Dataset Information

Normobaric oxygen: a novel approach for treating chronic cerebral circulation insufficiency.

Publications

Normobaric oxygen: a novel approach for treating chronic cerebral circulation insufficiency.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure